Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's analysis revealed that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
臨床和經濟評審研究所（ICER）已確定五種處方藥在2023年的價格上漲缺乏足夠的臨床證據來證明這些漲價的合理性。
Gilead Sciences Inc's (NASDAQ:GILD) Biktarvy, Johnson & Johnson's (NYSE:JNJ) Darzalex, Novartis AG's (NYSE:NVS) Entresto, Exelixis Inc (NASDAQ:EXEL) Cabometyx, and Pfizer Inc's (NYSE:PFE) Xeljanz are among the five drugs flagged for unsupported price increases.
吉利德科學公司（納斯達克：GILD）的Biktarvy，強生（紐交所：JNJ）的Darzalex，諾華製藥（紐交所：NVS）的Entresto，Exelixis公司（納斯達克：EXEL）的Cabometyx，以及輝瑞公司（紐交所：PFE）的Xeljanz是被指出價格上漲沒有支持的五種藥物。
These five drugs' unsupported net price increases produced $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
這五種藥物的沒有依據的淨價格上漲在2023年爲美國支付者增加了81500萬美元的額外成本。這些價格上漲顯著推動了整體支出激增。
ICER's analysis revealed that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
ICER的分析表明，名單上的其他五種藥物確實展示了新的臨床證據來證明其增加的成本是合理的。
Merck & Co Inc's (NYSE:MRK) Keytruda, AstraZeneca Plc's (NASDAQ:AZN) Imfinizi and Tagrisso, Bristol Myers Squibb & Co's (NYSE:BMY) Opdivo, and Amgen Inc's (NASDAQ:AMGN) Prolia
默沙東（紐交所：MRK）的Keytruda，阿斯利康（納斯達克：AZN）的Imfinizi和Tagrisso，百時美施貴寶（紐交所：BMY）的Opdivo，以及安進公司（納斯達克：AMGN）的Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
這些發現是ICER最新的無支持價格上漲（UPI）報告的一部分，該報告研究了過去一年淨價格大幅上漲的前10種藥物。
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
ICER研究副總裁Foluso Agboola博士強調了這些價格上漲的影響，指出它們超過了通脹率，並給醫療系統帶來了壓力。
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
ICER報告指出，吉利德的Biktarvy的批發採購成本上漲了5.9%，其漲價使美國支付者的額外藥物支出增加了35900萬美元。
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
根據ICER報告，Darzalex的價格在扣除折扣前上漲了7.6%，而Entresto上漲了6.2%，Cabometyx上漲了7.5%，Xeljanz上漲了6%。
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
這些價格上漲分別爲2023年美國藥品支出增加了19000萬美元、10800萬美元、8600萬美元和7200萬美元。
Methodology Behind ICER's Findings
ICER發現背後的方法論
- ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.
- The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.
- Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.
- ICER的評估遵循了2024年4月提出的詳細協議。該組織評估了符合標準的藥物，例如在美國營業收入中排名前250位，並且在其批發採購成本中超過消費者價格指數增長加2%。
- 該分析側重於區分由價值驅動的價格上漲與那些與新臨床證據無關的價格上漲。
- 製造商提供了意見，而ICER則審查已發佈的研究以尋找額外健康益處的證據。
- Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan
- 華納兄弟探索公司的股票在董事會批准重組計劃後急劇上升
Photo by MargJohnsonVA via Shutterstock
照片由MargJohnsonVA通過Shutterstock提供
譯文內容由第三人軟體翻譯。
